Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Acquisitions & Divestments (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $60.0 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 18.92% year-over-year to $60.0 million; the TTM value through Sep 2025 reached $261.5 million, down 62.91%, while the annual FY2024 figure was $271.2 million, 46.33% down from the prior year.
  • Change in Acquisitions & Divestments reached $60.0 million in Q3 2025 per ZNTL's latest filing, down from $70.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $505.3 million in Q4 2023 and bottomed at -$304.5 million in Q3 2023.
  • Average Change in Acquisitions & Divestments over 4 years is $92.5 million, with a median of $71.7 million recorded in 2024.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 342.28% in 2023, down 301.26% in 2023.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $114.2 million in 2022, then soared by 342.28% to $505.3 million in 2023, then plummeted by 85.85% to $71.5 million in 2024, then decreased by 16.08% to $60.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $60.0 million in Q3 2025, $70.0 million in Q2 2025, and $60.0 million in Q1 2025.